目的 观察夏枯草口服液联合¹³¹I治疗Graves病的疗效及对患者相关抗体的影响。方法 采用夏枯草口服液联合¹³¹I治疗Graves病患者（观察组96例），与单用¹³¹I治疗（对照组96例）进行疗效比较，并比较治疗前后促甲状腺素受体抗体（TRAb）、甲状腺球蛋白抗体（TGAb）及甲状腺过氧化酶抗体（TPOAb）水平变化。结果 观察组与对照组在治疗6个月后总有效率分别为92.7%、81.2%，两组差异显著（P<0.05）。两组治疗前TRAb、TGAb及TPOAb水平差异无统计学意义（P>0.05），观察组的TRAb水平6个月后下降明显，与对照组比较差异显著（P<0.05）。观察组及对照组治疗6个月后TGAb、TPOAb水平均升高，对照组尤为明显，两者比较差异显著（P<0.05）。结论 夏枯草口服液与¹³¹I联用能有效降低Graves病患者血清TRAb水平和升高TGAb及TPOAb水平，治疗效果明显优于单用¹³¹I治疗。

Objective To observe the therapeutic effect of Xiakucao Oral Liquid combined with ¹³¹I on Graves disease and its effect on antibodies. Methods The efficacy of 96 patients with Graves disease treated with Xiakucao Oral Liquid and ¹³¹I (observation group) was compared with those only treated with ¹³¹I (control group). The levels of TRAb, TGAb, and TPOAb were compared between the two groups before and after treatment. Results The efficacy after 6 months of treatment between the observation group and the control group was statistically different (P < 0.05). There were no significant differences in the levels of TRAb, TGAb, and TPOAb before the treatment between the two groups (P > 0.05). The TRAb level in the observation group decreased significantly after 6 months, and the difference between two groups was statistically significant (P < 0.01). The levels of TGAb and TPOAb increased in the two groups after 6 months of treatment, especially in the control group, and the differences were statistically significant (P < 0.05). Conclusion Xiakucao Oral Liquid combined with ¹³¹I can effectively reduce the levels of serum TRAb, TGAb, and TPOAb in patients with Graves disease, and the efficacy of Xiakucao Oral Liquid combined with ¹³¹I is significantly better than ¹³¹I treatment only.